Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)
This is a prospective phase II clinical trial to observe the efficacy and safety of Chidamide combined with DICE (Dexamethasone, Ifosfamide, Cisplatin and Etoposide) in patients with relapsed or refractory B-cell Non-Hodgkin's Lymphoma (NHL).
B-cell Non-Hodgkin's Lymphoma
DRUG: Chidamide plus DICE Regimen
objective response rate（ORR）, the total proportion of patients with complete response（CR or CRu）and partial response（PR）, every 6 weeks until 2 years
progression-free survival（PFS）, Time from treatment until disease progression or death, 2 years|events-free survival（EFS）, Time from treatment to disease progression, death, or discontinuation of treatment for any reason, 2 years|overall survival（OS）, Time from treatment until death from any cause, 2 years
Chidamide，a novel histone deacetylase inhibitor has been approved for the treatment of relapsed or refractory peripheral T-cell lymphoma in China. The aim of this study was to observe the efficacy and safety of Chidamide combined with DICE in patients with relapsed or refractory B-cell Non-Hodgkin's Lymphoma (NHL).